Dec 31, 2025 • The Business Journals
NEUTRAL
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts
In 2025, over 4,600 biotech workers in Massachusetts faced job losses as the industry contracted, with companies like Moderna and Sarepta leading the layoffs. This article provides a list of the companies affected and highlights the significant impact on the state's life sciences sector. The piece previews a detailed report on these layoffs within the Massachusetts life sciences industry.
Dec 31, 2025 • www.sharewise.com
SOMEWHAT-BEARISH
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Moderna (MRNA) closed down 2.38% in a recent trading session, underperforming the broader S&P 500, Dow, and Nasdaq markets. Despite this daily dip, the stock gained 28.93% over the past month, significantly outpacing the Medical sector. Analysts predict an EPS of -$2.79 and revenue of $683.27 million for its upcoming earnings release.
Dec 31, 2025 • Ventura County Star
NEUTRAL
Moderna to Host Investor Event – Analyst Day
Moderna, Inc. announced it will host an Investor Event – Analyst Day on Thursday, November 20, 2025, at 9:00 a.m. ET. The event will feature presentations from management detailing Moderna's development and commercial strategy and key business considerations. A live webcast and subsequent replay will be available on Moderna's investor website.
Dec 30, 2025 • ts2.tech
NEUTRAL
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook
Pfizer Inc. (NYSE:PFE) shares saw a small gain after TD Cowen reiterated its Hold rating and a $30 price target, despite negative long-term trends and investor focus on the company's 2026 outlook. The company projects 2026 revenue between $59.5 billion and $62.5 billion and adjusted earnings of $2.80 to $3.00 per share, acknowledging "bumpy" years ahead due to fading COVID demand, Medicaid pricing pressure, and patent expirations. Investors are looking for clarity on growth trajectory and how Pfizer will address these challenges in its upcoming Q4 and full-year 2025 report.
Dec 30, 2025 • Citeline News & Insights
SOMEWHAT-BEARISH
Genmab Pulls Plug On Acasunlimab Development In Pipeline Reset
Genmab has decided to discontinue the development of Acasunlimab as part of a pipeline reset. This decision comes after their recent acquisition of Merus for $8bn, indicating a strategic shift towards enhancing their pipeline. The company is re-evaluating its drug development focus.
Dec 30, 2025 • Investing.com
SOMEWHAT-BEARISH
Co-Diagnostics stock plunges after announcing 1-for-30 reverse split
Co-Diagnostics Inc. (NASDAQ:CODX) stock plummeted 13.8% after the company announced a 1-for-30 reverse stock split. This move is intended to bring Co-Diagnostics into compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will take effect on January 2, 2026, with all outstanding common shares, stock options, and warrants being proportionally adjusted.